News
Forbes Porter, from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and coauthors assessed the prevalence of anti-AAV9 and anti-AAV2 neutralizing antibodies ...
Spark Therapeutics/Novartis' LUXTURNA (AAV2-hRPE65v2; voretigene neparvovec) Overview LUXTURNA (voretigene neparvovec-rzyl, AAV2-hRPE65v2) is a one-time gene therapy designed to treat vision loss ...
Hosted on MSN15d
Assessing the prevalence of neutralizing antibodies in individuals with Niemann-Pick diseaseForbes Porter, from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and co-authors assessed the prevalence of anti-AAV9 and anti-AAV2 neutralizing antibodies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback